Clinical trials: Coronavirus Sars-Associated
Covid-19
Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia
The trial aims to assess the impact of cheap, licenced and widely available investigational products on the natural history of SARS-CoV-2 infection in 2 groups of patients - those with mild or moderate pneumonia (Cohort 1) and…
- Trial name
- PaTS-COVID (NCT04703608)
- Testing
- Ivermectin, ASP
- Where
- The Gambia
- Volunteers
- 1,200 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Coronavirus Infections, Diabetes Mellitus
Covid-19 and Diabetes in West of Algeria
By Jan 7, 2020, Chinese scientists had isolated a novel coronavirus, from patients with virus-infected pneumonia. The WHO designated later this virus as COVID-19 (coronavirus disease 2019).
- Conditions
- Coronavirus Infections, Diabetes Mellitus, Prevalence, Risk Factors
- Trial name
- COVIDIAB-13 (NCT04412746)
- Testing
- MANAGEMENT OF COVID-19
- Where
- Algeria
- Volunteers
- 100 people
- Sponsor
- Laboratoire De Recherche Sur Le Diabete, Université de Tlemcen
Sars-CoV-2 Infection, Lung Fibrosis
Low-field Magnetic Resonance Imaging of Pediatric COVID-19
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a new coronavirus and identified causative agent of COVID-19 disease. They predominantly cause mild colds but can sometimes cause severe pneumonia.
- Conditions
- Sars-CoV-2 Infection, Lung Fibrosis, Covid19
- Trial name
- DECRYPT (NCT04990531)
- Testing
- Low-field magnetic resonance imaging, Blood sample
- Where
- Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
COVID - 19, Diabetes Mellitus
DIFFERENT SARS-COV-2 VARIANTS' EFFECT ON THE COURSE OF COVID-19 IN ESTONIAN CHILDREN
The study focuses on Estonian children under 18 who had COVID-19 from 27.02.2020 to 01.03.2023. The main aim is to find out the risk factors for severe COVID-19 in children.
- Conditions
- COVID - 19, Diabetes Mellitus, Post-COVID Conditions, MIS-C Associated With COVID-19
- Trial name
- NCT06784713
- Where
- Estonia
- Volunteers
- 127,277 people
- Sponsor
- University of Tartu
Covid19, MIS-C Associated With COVID-19
Pediatric COVID Outcomes Study (PECOS)
This is a multisite prospective observational study to evaluate the clinical sequelae of symptomatic and asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the pediatric population, including…
- Conditions
- Covid19, MIS-C Associated With COVID-19, MIS-C Multisystem Inflammatory Syndrome in Children, SARS-CoV2 Infection
- Trial name
- NCT04830852
- Where
- 2 sites in United States
- Volunteers
- 1,097 people, healthy volunteers welcome
- Sponsor
- Children's National Research Institute
Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-Cov-2
Paediatric Inflammatory Multisystem Syndrome During COVID-19 Pandemic
During the COVID-19 pandemic, a small minority of children have been presenting to acute paediatric services with a new syndrome, Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS-Cov-2 (PIMS-TS).
- Trial name
- NCT04761913
- Where
- 6 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Anglia Ruskin University
COVID, SARS-CoV 2
Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est
Healthcare centers treated several hundreds of patients with Covid-19 and prospectively gathered information in electronic format between March, 2020 to April, 2020.
- Trial name
- NCT04366206
- Where
- 2 sites in France
- Volunteers
- 143 people
- Sponsor
- Centre Hospitalier Intercommunal Robert Ballanger
Paediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS)
Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)
The study is to provide reliable estimates of the effect of study treatment on hospital length of stay through to 28 days after randomisation.
- Trial name
- NCT04826588
- Testing
- Methylprednisolone sodium succinate 10 mg/kg intravenously, Human normal immunoglobulin (IVIg)
- Where
- 10 sites in Switzerland
- Volunteers
- 76 people
- Sponsor
- University Children's Hospital Basel
Covid19
TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
Investigators conducted this study to see the effectiveness of Tocilizumab in COVID-19 participants who were in cytokine release syndrome and there was also a control group who received steroids(RECOVERY TRIAL wasn't published or…
- Trial name
- NCT04730323
- Testing
- Tocilizumab
- Where
- Pakistan
- Volunteers
- 93 people
- Sponsor
- FMH College of Medicine and Dentistry
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Follow-up of Covid-19 Long Term Sequelae
The protocol, in accordance with the objectives of ORCHESTRA project - Work Package 2, aims at investigating the characteristics and determinants of COVID-19 long-term sequelae.
- Conditions
- COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Bronchitis, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05097677
- Testing
- Not applicable (observational study)
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 7,599 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Cytokine Storm (Covid-19)
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
This was a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with placebo + SoC therapy, in patients aged ≥12 years…
- Trial name
- RUXCOVID (NCT04362137)
- Testing
- Ruxolitinib
- Where
- 61 sites in United States, Argentina and 10 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Coronavirus Infection, Severe Acute Respiratory Syndrome
COVID-19 Health Professional Impact Study
The COVID-19 (coronavirus) pandemic has had a huge impact on healthcare resources and staff in the UK. Understanding the key risk factors associated with infection amongst healthcare workers is essential for future pandemic…
- Trial name
- CHIP (NCT04527432)
- Testing
- Survey, SARS-CoV-2 antibody test
- Where
- United Kingdom
- Volunteers
- 1,504 people, healthy volunteers welcome
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Coronavirus
Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID-19.
In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, in China. In a few weeks, the number of confirmed cases of SARS-CoV-2 infection has dramatically increased, with almost 150'000…
- Trial name
- NCT04322279
- Testing
- Serology, Sequencing
- Where
- 16 sites in France, French Guiana
- Volunteers
- 81 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
COVID-19
Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.
- Trial name
- NCT04377620
- Testing
- Ruxolitinib
- Where
- 36 sites in United States, Russia
- Volunteers
- 211 people
- Sponsor
- Incyte Corporation
ME/CFS, CFS/ME
Multi-Center Registry for ME/CFS
The ME/CFS study (MECFS-R) aims to create a large-scale registry that provides data on epidemiology, phenotypes, and disease trajectories of and health care for ME/CFS at any age in Germany, which can be used for future clinical…
- Conditions
- ME/CFS, CFS/ME, ME/CFS Following EBV-associated Infectious Mononucleosis, ME/CFS Following COVID-19
- Trial name
- MECFS-R (NCT05778006)
- Where
- Germany
- Volunteers
- 650 people
- Sponsor
- Technical University of Munich
Coronavirus Infections, Coronavirus Sars-Associated
Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19
The present work proposes to find if a bio-active composite in the hemolymph or plasma of the freshwater bivalve Anodonta cygnea is able to offer immunity and specificity for meliorating the major symptoms in human SARS and…
- Conditions
- Coronavirus Infections, Coronavirus Sars-Associated, SARS (Severe Acute Respiratory Syndrome), COVID-19
- Trial name
- NCT05054075
- Testing
- Marine liquid and fluids, Impregnation, Incubation
- Where
- 2 sites in Portugal
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Universidade do Porto
COVID-19 (Coronavirus Disease 2019), COVID-19 Pandemic
University Hospital of Ioannina COVID-19 (Coronavirus Disease 2019) Registry
COVID-19 (Coronavirus Disease 2019) Registry of University Hospital of Ioannina. Retrospective datasource registry with quantitative and qualitative patient data from the hospital medical records.
- Conditions
- COVID-19 (Coronavirus Disease 2019), COVID-19 Pandemic, COVID-19 Pneumonia, COVID-19 Respiratory Infection
- Trial name
- NCT05534074
- Where
- Greece
- Volunteers
- 2,500 people
- Sponsor
- University Hospital, Ioannina